^
    1d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    1d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    3d
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    3d
    Sacituzumab tirumotecan plus Immune Checkpoint Inhibitor as Neoadjuvant Therapy for Resectable Stage IIIA–IIIB (N2) Non-small-cell Lung Cancer: A Single-arm, Single-center, Phase II Trial (ChiCTR2600116542)
    P2, N=34, Not yet recruiting, The General Hospital of the Eastern Theater Command of the People's Liberation Army of China; The General Hospital of the Eastern Theater Command of t
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    3d
    Neoadjuvant immunotherapy with or without chemotherapy and minimally invasive esophagectomy in elderly patients for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, multicenter phase II clinical study (ChiCTR2500111929)
    P2, N=62, Recruiting, Shanghai Geriatric Medical Center; Shanghai Geriatric Medical Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    3d
    Tumor Location Significantly Correlates With PD-L1 Status in Patients With Small Sized Non-small Cell Lung Cancer. (PubMed, Anticancer Res)
    PD-L1 expression status significantly correlated with CTR, histological type and tumor location. This is the first report demonstrating a significant correlation between PD-L1 expression and tumor location in NSCLC. We believe that differences in the cancer microenvironment based on tumor location influence PD-L1 expression status in cancer cells.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx
    11d
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (clinicaltrials.gov)
    P3, N=1210, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed
    11d
    META-1: Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels (clinicaltrials.gov)
    P2, N=275, Not yet recruiting, UNICANCER
    New P2 trial • IO Companion diagnostic • PD(L)-1 companion diagnostic
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc)
    12d
    G360-IIT: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (clinicaltrials.gov)
    P2, N=108, Recruiting, Hackensack Meridian Health | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    13d
    Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) (clinicaltrials.gov)
    P2, N=37, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 expression • ER negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    16d
    Renal cell carcinoma with biphasic morphology: A cohort showing similar morphology but distinct clinicopathological and molecular features. (PubMed, Pathol Res Pract)
    In TFE3-rearranged RCC, the fusion gene might influence morphology or PD-L1 expression, thereby be likely to affect the efficacy of immunotherapy. Assessment of a combination of histological morphology, immunophenotype, and genetic alterations can facilitate precise pathological diagnosis of RCC, supporting personalized targeted therapy and prognosis assessment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • GPNMB (Glycoprotein Nmb) • CTSK (Cathepsin K) • TFEB (Transcription Factor EB 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    17d
    A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non-small-cell lung cancer. (PubMed, Clin Transl Immunology)
    These findings underscore the crucial role of synergistic treatment in augmenting the efficacy of ICIs. The crosstalk between neutrophils and B cells in the orchestration of ICIs therapy for NSCLC was further elucidated through the roles of HSD17B11, SORL1, and TREM1.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • FOXP3 (Forkhead Box P3) • SORL1 (Sortilin Related Receptor 1)
    |
    PD-L1 IHC 22C3 pharmDx